Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2020-03-25 Major Shareholding Noti…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease in holdings by Yuyang D&U in GtreeBNT) and is filed with the Financial Supervisory Service (FSS). This falls under the category of Major Shareholding Notification.
2020-03-25 Korean
전환가액의조정(제10회차)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (HLB Therapeutics, formerly GtreeBNT) regarding the adjustment of the conversion price of convertible bonds (CB). This type of disclosure, which details changes to the terms of financial instruments like convertible bonds due to market price fluctuations, falls under capital structure and financing updates. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most appropriate category for adjustments to conversion prices of debt instruments.
2020-03-23 Korean
[기재정정]최대주주변경
Director's Dealing Classification · 95% confidence The document is a regulatory filing from a Korean company (GtreeBNT) regarding a change in the 'Maximum Shareholder' (controlling shareholder). It details the correction of a previous filing concerning share ownership percentages and the status of the controlling entity. This type of disclosure regarding changes in major shareholding or control structure falls under the category of Major Shareholding Notification (MRQ) as it pertains to significant changes in ownership levels and control.
2020-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the share acquisition (insider trading) by a director (Won S. Yang) of GTreeBNT. This type of filing is classified as 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2020-03-20 Korean
최대주주변경
Board/Management Information Classification · 95% confidence The document is a formal regulatory filing from a Korean company (HLB Therapeutics, formerly GtreeBNT) announcing a change in the largest shareholder. It details the 'before' and 'after' shareholding structure, the reason for the change (disposal of shares by the previous major shareholder), and provides biographical information on the new major shareholder. This type of disclosure is a standard regulatory requirement for material corporate changes and does not fit into specific categories like earnings, dividends, or board appointments, making 'Regulatory Filings' (RNS) the most appropriate classification.
2020-03-20 Korean
감사보고서제출
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS).
2020-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.